---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-008639"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:44:58.955469+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Arrowhead shareholders elect eight directors, approve executive compensation and share increase

## Summary
- All eight director nominees elected; votes ranged from ~62.8M to ~67.8M in favor.
- Advisory vote on executive compensation passed with 62,683,718 for, 7,119,440 against.
- Amendment to increase authorized common shares approved: 80,352,213 for, 8,279,373 against.
- Ratification of Rose Snyder & Jacobs as auditors passed: 86,613,251 for, 1,296,520 against.
- Broker non-votes of ~18.7M were recorded on director election and executive compensation proposals.

## SEC filing metadata
- accession: 0001628280-23-008639
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/0001628280-23-008639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/arwr-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-008639
- JSON: https://secwatch.observer/filing/0001628280-23-008639.json
- Plain text: https://secwatch.observer/filing/0001628280-23-008639.txt

## Key facts
- Shareholder Votes
  ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Ratification of Rose, Snyder & Jacobs as independent auditors at the 2023-03-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-03-16
  source text: Ratification of Rose, Snyder & Jacobs as Independent Auditors of the Company 86,613,251 FOR 1,296,520 AGAINST 863,437 ABSTAIN 0 NON VOTES
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/0001628280-23-008639-index.htm
- Shareholder Votes
  ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Election of eight directors to serve until next annual meeting at the 2023-03-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-03-16
  source text: Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 67,160,632 2,517,893 405,240 18,689,443 Michael S. Perry 65,416,779 4,172,284 494,702 18,689,443 Christopher Anzalone 67,517,726 2,257,619 308,420 18,689,443 Marianne De Backer 64,099,823 5,531,033 452,909 18,689,443 Mauro Ferrari 62,760,154 6,726,045 597,566 18,689,443 Adeoye Olukoton 65,203,181 4,295,706 584,878 18,689,443 William Waddill 63,143,044 6,415,395 525,326 18,689,443 Victoria Vakiener 67,756,449 1,797,645 529,671 18,689,443
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/0001628280-23-008639-index.htm
- Shareholder Votes
  ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Approval of amendment to increase authorized shares of common stock at the 2023-03-16 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-03-16
  source text: Approval of Amendment to Increase Authorized Shares of Common Stock 80,352,213 FOR 8,279,373 AGAINST 141,622 ABSTAIN 0 NON VOTES
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/0001628280-23-008639-index.htm
- Shareholder Votes
  ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation at the 2023-03-16 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-03-16
  source text: Advisory Vote to Approve Executive Compensation 62,683,718 FOR 7,119,440 AGAINST 280,607 ABSTAIN 18,689,443 NON VOTES
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023008639/0001628280-23-008639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.